RET and cancer: We assessed a panel of 53 therapeutic compounds (Figure S6) including clinically approved RAS/MAPK pathway inhibitors (e. g., vemurafenib, axitinib), RTK inhibitors including inhibitors of RET (vandetanib, cabozantinib) and epidermal growth factor receptor (EGFR; erlotinib, lapatinib), SRC inhibitors, etc. We tested inhibitors targeting the proteasome, histone deacetylases (HDACs), and HSP90, which have shown promise as therapies in different RAS-dependent cancer paradigms.